Initial results of a study investigating mosunetuzumab for treatment of relapsed follicular lymphoma.
Home / Resource Library / Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis